Drug Type CAR-T |
Synonyms AntiEGFR/IL13R2 CAR T cell therapy, AntiEGFR/IL13Ra2 CAR T cell therapy, AntiEGFR/IL13Ralfa2 CAR T cell therapy |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), IL-13Rα2 inhibitors(Interleukin-13 receptor subunit alpha-2 inhibitors), Gene transference + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR mutation Glioblastoma | Phase 1 | US | 24 Feb 2023 | |
EGFR mutation Glioblastoma | Phase 1 | US | 24 Feb 2023 | |
Recurrent Glioblastoma | Phase 1 | US | 24 Feb 2023 | |
Recurrent Glioblastoma | Phase 1 | US | 24 Feb 2023 | |
Glioblastoma | Preclinical | US | Tmunity Therapeutics, Inc.Startup | - |